These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 26625828)
1. Predictive Value of IHC4 Score for Pathological Response to Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer. Elsamany S; Elmorsy S; Alzahrani A; Rasmy A; Abozeed WN; Mohammed AA; Sherisher MA; Abbas MM; Mashhour M Asian Pac J Cancer Prev; 2015; 16(17):7975-9. PubMed ID: 26625828 [TBL] [Abstract][Full Text] [Related]
2. Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer. Sheri A; Smith IE; Hills M; Jones RL; Johnston SR; Dowsett M Breast Cancer Res Treat; 2017 Jul; 164(2):395-400. PubMed ID: 28447240 [TBL] [Abstract][Full Text] [Related]
3. A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer. Tan W; Luo W; Jia W; Liang G; Xie X; Zheng W; Song E; Su F; Gong C Oncotarget; 2016 Dec; 7(52):87312-87322. PubMed ID: 27894097 [TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709 [TBL] [Abstract][Full Text] [Related]
5. Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers. Park YH; Im SA; Cho EY; Ahn JH; Woo SY; Kim S; Keam B; Lee JE; Han W; Nam SJ; Park IA; Noh DY; Yang JH; Ahn JS; Im YH Oncology; 2014; 86(5-6):279-88. PubMed ID: 24903080 [TBL] [Abstract][Full Text] [Related]
6. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205 [TBL] [Abstract][Full Text] [Related]
7. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status. Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606 [TBL] [Abstract][Full Text] [Related]
8. Predictive Value of the Pattern of β-Catenin Expression for Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Elsamany S; Elemam O; Elmorsy S; Alzahrani A; Abbas MM Asian Pac J Cancer Prev; 2016; 17(8):4089-93. PubMed ID: 27644666 [TBL] [Abstract][Full Text] [Related]
9. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer. Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324 [TBL] [Abstract][Full Text] [Related]
10. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients. Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870 [TBL] [Abstract][Full Text] [Related]
11. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer. Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211 [TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients. Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab. Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689 [TBL] [Abstract][Full Text] [Related]
14. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response. Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684 [TBL] [Abstract][Full Text] [Related]
15. The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Eryilmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Coskun HS Asian Pac J Cancer Prev; 2014; 15(18):7737-40. PubMed ID: 25292055 [TBL] [Abstract][Full Text] [Related]
16. The Impact of Facility Volume on Rates of Pathologic Complete Response to Neoadjuvant Chemotherapy Used in Breast Cancer. Ajmani GS; James TA; Kantor O; Wang CH; Yao KA Ann Surg Oncol; 2017 Oct; 24(11):3157-3166. PubMed ID: 28685357 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600 [TBL] [Abstract][Full Text] [Related]
18. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy. De La Cruz LM; Harhay MO; Zhang P; Ugras S Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025 [TBL] [Abstract][Full Text] [Related]
19. Mean Platelet Volume as an Independent Predictive Marker for Pathologic Complete Response after Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer. Mutlu H; Eryılmaz MK; Musri FY; Gunduz S; Salim DK; Coskun HS Asian Pac J Cancer Prev; 2016; 17(4):2089-92. PubMed ID: 27221900 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. Hayashi M; Yamamoto Y; Ibusuki M; Fujiwara S; Yamamoto S; Tomita S; Nakano M; Murakami K; Iyama K; Iwase H Ann Surg Oncol; 2012 Sep; 19(9):3042-9. PubMed ID: 22476757 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]